Screener
Inhibrx Biosciences, Inc. INBX Business Segments — Net income (loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Inhibrx Biosciences, Inc.’s 10-K, filed March 19, 2026.
- Filed
- Mar 19, 2026, 4:00 PM EDT
- Fiscal year
- FY2025
- Accession
- 0002007919-26-000006
| Line item | YEAR ENDEDDECEMBER 31, 2025 | YEAR ENDEDDECEMBER 31, 2024 |
|---|---|---|
| Total other income (expense) | (5,028) | 2,019,022 |
| Income (loss) before provision for income taxes | (140,053) | 1,687,574 |
| Provision for income taxes | 2 | 2 |
| Net income (loss) | $(140,055) | $1,687,572 |
| Earnings (loss) per share | ||
| Basic | $(9.04) | $114.01 |
| Diluted | $(9.04) | $112.62 |
| Shares used in computing earnings (loss) per share |
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is Inhibrx Biosciences, Inc.'s business segments — net income (loss)?
- Inhibrx Biosciences, Inc. (INBX) reported business segments — net income (loss) of -$32.83M in Q4 2025.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s business segments — net income (loss)?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s business segments — net income (loss) has grown at a -23.8% compound annual growth rate (CAGR), from -$241.36M to -$140.06M.
- What does business segments — net income (loss) mean?
- Represents the bottom-line financial performance of the reportable segment after accounting for all revenues and operating expenses. It is the primary indicator of the segment's overall profitability and its contribution to the company's total financial health.
Ask your AI about Inhibrx Biosciences, Inc.'s business segments — net income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude